Cargando…
Hemoadsorption with CytoSorb shows a decreased observed versus expected 28-day all-cause mortality in ICU patients with septic shock: a propensity-score-weighted retrospective study
BACKGROUND AND AIMS: Innovative treatment modalities have not yet shown a clinical benefit in patients with septic shock. To reduce severe cytokinaemia, CytoSorb as an add-on to continuous renal replacement therapy (CRRT) showed promising results in case reports. However, there are no clinical trial...
Autores principales: | Brouwer, Willem Pieter, Duran, Servet, Kuijper, Martijn, Ince, Can |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6749645/ https://www.ncbi.nlm.nih.gov/pubmed/31533846 http://dx.doi.org/10.1186/s13054-019-2588-1 |
Ejemplares similares
-
Hemoadsorption by CytoSorb in septic patients: a case series
por: Kogelmann, Klaus, et al.
Publicado: (2017) -
Experience with hemoadsorption (CytoSorb(®)) in the management of septic shock patients
por: Mehta, Yatin, et al.
Publicado: (2020) -
Sublingual Microcirculatory Evaluation of Extracorporeal Hemoadsorption with CytoSorb® in Abdominal Sepsis: A Case Report
por: Duran, Servet, et al.
Publicado: (2022) -
Pharmacokinetics of anti-infective agents during CytoSorb hemoadsorption
por: Schneider, Antoine G., et al.
Publicado: (2021) -
Hemoadsorption with CytoSorb(®) and the early course of linezolid plasma concentration during septic shock
por: Köhler, Thomas, et al.
Publicado: (2021)